Vistagen to acquire Pherin for ~12.4M shares, gaining full IP rights to PH94B and PH10

Vistagen Therapeutics, Inc.

Vistagen will issue ~12.4M shares of common stock and a nominal cash payment (under $50k) to acquire Pherin.
Acquisition eliminates all future royalty and milestone payment obligations related to PH94B and PH10.
Pipeline expands with three new pherine candidates: PH15 (cognition), PH80 (migraine/hot flashes), PH284 (appetite disorders).
PH94B in Phase 3 for social anxiety disorder and Phase 2 for adjustment disorder with anxiety; PH10 in development for major depressive disorder.
Closing subject to Pherin stockholder approval and other customary conditions; lock-up of 180 days for certain Pherin holders.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vistagen Therapeutics, Inc. entered into Agreement and Plan of Merger with Pherin Pharmaceuticals, Inc. and Kevin McCarthy as Stockholder Representative (effective 2022-12-20).

Action: entry
Agreement: merger
Counterparty: Pherin Pharmaceuticals, Inc. and Kevin McCarthy as Stockholder Representative
Effective: 2022-12-20

Exact text from the filing

On December 20, 2022, Vistagen Therapeutics, Inc. (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, VTGN Merger Sub, Inc., a wholly-owned subsidiary of the Company (“ Merger Sub ”), Pherin Pharmaceuticals, Inc. (“ Pherin ”), and Kevin McCarthy in the capacity of Stockholder Representative.

View on SEC.gov

300 material agreements filed in the last 30 days. Browse all material agreements →

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001851734-22-000740

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.